Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VVUS - VIVUS Inc.

Previous close
0.4665
0   0%

Share volume: 0
Last Updated: Thu 16 Jul 2020 06:00:00 AM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$0.47
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 46%
Dept financing 50%
Liquidity 31%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.47
P/E Ratio 
N/A
DAY RANGE
$0.47 - $0.47
EPS 
-$2.70
52 WEEK RANGE
$0.44 - $4.75
52 WEEK CHANGE
-$86.28
MARKET CAP 
8.335 M
YIELD 
N/A
SHARES OUTSTANDING 
17.868 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$16,616,568
AVERAGE 10 VOLUME 
$3,252,867
AVERAGE 30 VOLUME 
$1,679,610
Company detail
CEO: John P. Amos
Region: US
Website: http://www.vivus.com
Employees: 59
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Recent news